nu6102 and nu 6027

nu6102 has been researched along with nu 6027 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bentley, J; Boyle, FT; Calvert, AH; Cheng, Y; Curtin, NJ; Endicott, JA; Golding, BT; Griffin, RJ; Hardcastle, IR; Jewsbury, P; Mesguiche, V; Newell, DR; Noble, ME; Parsons, RJ; Pratt, DJ; Sayle, KL; Wang, LZ1
Caldon, EC; Tadesse, S; Tilley, W; Wang, S1

Reviews

1 review(s) available for nu6102 and nu 6027

ArticleYear
Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.
    Journal of medicinal chemistry, 2019, 05-09, Volume: 62, Issue:9

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclin-Dependent Kinase 2; Drug Design; Humans; Neoplasms; Protein Binding; Protein Conformation; Protein Kinase Inhibitors

2019

Other Studies

1 other study(ies) available for nu6102 and nu 6027

ArticleYear
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.
    Bioorganic & medicinal chemistry letters, 2003, Sep-15, Volume: 13, Issue:18

    Topics: Antineoplastic Agents; CDC2 Protein Kinase; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Structure; Protein Binding; Pyrimidines; Structure-Activity Relationship

2003